Alcrist 1mg Injection
Marketer
Alkem Laboratories Ltd
Salt Composition
Vincristine (1mg)
Overview Alcrist 1mg Injection
Oncaspar (1mg injection) is a chemotherapy agent indicated for various cancers including breast, non-small cell lung, pancreatic, renal, hematologic malignancies (like multiple myeloma and lymphomas), and bone cancer. Administered intravenously under medical supervision, the dosage and frequency are determined by your physician based on your specific condition and may vary. Strict adherence to the prescribed regimen is crucial; incorrect usage or overdose can lead to severe adverse reactions. While therapeutic effects might not be immediately apparent (weeks or months may pass), discontinue use only as directed by your doctor. Common side effects include alopecia, peripheral neuropathy (numbness and tingling in extremities), and constipation. Reduced white blood cell counts, increasing infection risk, are possible, as is uric acid-induced kidney impairment. Regular blood tests monitoring blood cell counts, cardiac function, hepatic function, and uric acid levels are necessary. Inform your doctor about all concurrent medications, as interactions are possible. Use during pregnancy or breastfeeding is contraindicated; effective contraception for both partners is essential throughout treatment. Avoid direct eye contact to prevent irritation.
Uses of Alcrist 1mg Injection
Malignancies affecting breast tissue, lungs (non-small cell), pancreas, kidneys, blood cells, bone marrow (multiple myeloma), lymphatic system, and bone.
Major Benefits of Alcrist 1mg Injection:
This medication will be administered by your healthcare provider; please do not self-medicate.
Common Side effects of Alcrist 1mg Injection:
- Hair loss
- Peripheral neuropathy (tingling and numbness of feet and hand)
- Constipation
How to use Alcrist 1mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
How Alcrist 1mg Injection works:
Alcrist 1mg Injection inhibits DNA replication within cancerous cells, thereby halting their proliferation and growth.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Alcrist 1mg Injection lacks established safety data. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Administering Alcrist 1mg Injection during pregnancy poses a confirmed risk to fetal development and is therefore inadvisable. Exceptions may exist in life-threatening circumstances where a physician deems the potential benefits outweigh the inherent dangers. Physician consultation is essential.
Breast feedingUNSAFE
Administering Alcrist 1mg Injection while breastfeeding is contraindicated. Evidence indicates potential infant toxicity from this medication.
DrivingUNSAFE
Administering Alcrist 1mg Injection might induce adverse reactions that could impair driving capabilities.
KidneyCAUTION
Patients with kidney impairment should use Alcrist 1mg Injection cautiously; dosage modification may be necessary. Physician consultation is advised.
LiverCAUTION
Patients with hepatic impairment should use Alcrist 1mg Injection cautiously; dosage modification may be necessary. Physician consultation is advised.
What if you forget to take Alcrist 1mg Injection :
NA
Facts to Know About Alcrist 1mg Injection
| Label | Value |
|---|---|
| Chemical Classification | Vinca-derived anticancer agents |
| Developing Habits | No. |
| Treatment Category | Cancer Medications |
| Action Category | Vinca Alkaloid Antimicrotubule Agents |
3,018 People bought this recently